Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
Lakhani NJ, Chow LQM, Gainor JF, LoRusso P, Lee KW, Chung HC, Lee J, Bang YJ, Hodi FS, Kim WS, Santana-Davila R, Fanning P, Squifflet P, Jin F, Kuo TC, Wan HI, Pons J, Randolph SS, Messersmith WA. Lakhani NJ, et al. Among authors: squifflet p. Lancet Oncol. 2021 Dec;22(12):1740-1751. doi: 10.1016/S1470-2045(21)00584-2. Epub 2021 Nov 15. Lancet Oncol. 2021. PMID: 34793719 Clinical Trial.
Neoadjuvant capecitabine and docetaxel (plus trastuzumab): an effective non-anthracycline-based chemotherapy regimen for patients with locally advanced breast cancer.
Wildiers H, Neven P, Christiaens MR, Squifflet P, Amant F, Weltens C, Smeets A, van Limbergen E, Debrock G, Renard V, Van Eenoo L, Wynendaele W, Paridaens R. Wildiers H, et al. Among authors: squifflet p. Ann Oncol. 2011 Mar;22(3):588-594. doi: 10.1093/annonc/mdq406. Epub 2010 Aug 13. Ann Oncol. 2011. PMID: 20709813 Free article. Clinical Trial.
Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis.
Saad ED, Squifflet P, Burzykowski T, Quinaux E, Delaloge S, Mavroudis D, Perez E, Piccart-Gebhart M, Schneider BP, Slamon D, Wolmark N, Buyse M. Saad ED, et al. Among authors: squifflet p. Lancet Oncol. 2019 Mar;20(3):361-370. doi: 10.1016/S1470-2045(18)30750-2. Epub 2019 Jan 29. Lancet Oncol. 2019. PMID: 30709633 Free PMC article.
Delivery of adjuvant sequential dose-dense FEC-Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence.
Wildiers H, Dirix L, Neven P, Prové A, Clement P, Squifflet P, Amant F, Skacel T, Paridaens R. Wildiers H, et al. Among authors: squifflet p. Breast Cancer Res Treat. 2009 Mar;114(1):103-12. doi: 10.1007/s10549-008-9970-z. Epub 2008 Mar 16. Breast Cancer Res Treat. 2009. PMID: 18344024 Clinical Trial.
Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer.
Wildiers H, Fontaine C, Vuylsteke P, Martens M, Canon JL, Wynendaele W, Focan C, De Greve J, Squifflet P, Paridaens R. Wildiers H, et al. Among authors: squifflet p. Breast Cancer Res Treat. 2010 Sep;123(2):463-9. doi: 10.1007/s10549-010-1066-x. Epub 2010 Jul 22. Breast Cancer Res Treat. 2010. PMID: 20652398 Clinical Trial.
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 Therapy.
Squifflet P, Saad ED, Loibl S, van Mackelenbergh MT, Untch M, Rastogi P, Gianni L, Schneeweiss A, Conte P, Piccart M, Bonnefoi H, Jackisch C, Nekljudova V, Tang G, Valagussa P, Neate C, Gelber R, Poncet C, Heinzmann D, Denkert C, Geyer CE Jr, Cortes J, Guarneri V, de Azambuja E, Cameron D, Ismael G, Wolmark N, Cortazar P, Buyse M; CTNeoBC Project. Squifflet P, et al. J Clin Oncol. 2023 Jun 1;41(16):2988-2997. doi: 10.1200/JCO.22.02363. Epub 2023 Mar 28. J Clin Oncol. 2023. PMID: 36977286
Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.
van Mackelenbergh MT, Loibl S, Untch M, Buyse M, Geyer CE Jr, Gianni L, Schneeweiss A, Conte P, Piccart M, Bonnefoi H, Jackisch C, Nekljudova V, Tang G, Valagussa P, Neate C, Gelber R, Poncet C, Squifflet P, Saad ED, Heinzmann D, Denkert C, Rastogi P, Cortes J, Guarneri V, de Azambuja E, Cameron D, Ismael G, Wolmark N, Cortazar P; CTNeoBC project. van Mackelenbergh MT, et al. Among authors: squifflet p. J Clin Oncol. 2023 Jun 1;41(16):2998-3008. doi: 10.1200/JCO.22.02241. Epub 2023 Apr 19. J Clin Oncol. 2023. PMID: 37075276
Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia.
Buyse M, Squifflet P, Lange BJ, Alonzo TA, Larson RA, Kolitz JE, George SL, Bloomfield CD, Castaigne S, Chevret S, Blaise D, Maraninchi D, Lucchesi KJ, Burzykowski T. Buyse M, et al. Among authors: squifflet p. Blood. 2011 Jun 30;117(26):7007-13. doi: 10.1182/blood-2011-02-337725. Epub 2011 Apr 25. Blood. 2011. PMID: 21518931 Free PMC article.
14 results